Focus: Median Technologies is an imaging phenomics company specializing in AI-powered oncology solutions, including iCRO (imaging central lab) and clinical trial support services. Founded in 2024 and publicly listed, the company operates from Shanghai with a focus on early cancer detection and trial imaging analysis.
Profile data last refreshed 11h ago · AI intelligence enriched 2mo ago
Stable — net +4 jobs in 30d
4 added, 0 removed. Backfill posture.
Median Technologies is a high-risk, high-upside early-stage play for candidates seeking exposure to AI-oncology innovation, but financial distress and minimal hiring suggest wait-and-see prudence unless you have deep expertise in imaging biomarkers or iCRO operations.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Median Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Median Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of July 31, 2026 - Yahoo Finance
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of July 31, 2026 Yahoo Finance
25 Healthcare AI Use Cases with Examples - AIMultiple
25 Healthcare AI Use Cases with Examples AIMultiple
Median Technologies and Olea sign partnership for lung cancer device - Yahoo Finance
Median Technologies and Olea sign partnership for lung cancer device Yahoo Finance
Median Technologies partners with Canon Medical to achieve lung cancer screening goals - Mugglehead Investment Magazine
Median Technologies partners with Canon Medical to achieve lung cancer screening goals Mugglehead Investment Magazine
Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening - Business Wire
Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening Business Wire
Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications Across the eyonis® Portfolio - BioSpace
Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications Across the eyonis® Portfolio BioSpace
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo